Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

2yrs ago Private Equity privateequitywire Views: 548

NPIF – Mercia Equity Finance invests GBP1.4m in medtech startup

Submitted 10/05/2021 - 3:36pm

A medtech start-up whose sensor technology could improve outcomes for patients having knee replacement operations has raised GBP1.4 million to bring its device to market.

Eventum Orthopaedics has secured funding from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, Mercia’s EIS funds and private investors including several world-leading orthopaedic surgeons.     
 
Based in Ilkley, Yorkshire, the company was founded by John Naybour and Paul Atherton, who between them have almost 50 years’ experience in the field of orthopaedics and previously held senior roles with Johnson & Johnson. They have been joined by Mike Cripps, the former MD of Leeds-based Panintelligence, as Non-Executive Director and Jon Gonzales as Finance Director.
 
Around 2 million patients a year worldwide undergo a total knee replacement, and this is expected to rise to 3.5 million by 2030. However studies suggest that up to 20 per cent of patients are dissatisfied with their outcome. Eventum believes that the key to improving success rates is a greater focus on the positioning of the kneecap, which plays a significant role in the overall function of the knee.
 
Having created early prototypes with input from eminent surgeons worldwide, Eventum has now developed a unique and innovative device that will be the first to provide real-time measurements of this area during the operation, enabling surgeons to improve their decision making.
 
The funding will allow the team to finalise development and bring the product to market in 2022. As part of the investment Alan Ashby, who has held senior roles with international medical companies, has been appointed as Non-Executive Chair.
 
John Naybour, Eventum’s CEO, says: “I have spent my working life involved in developing products to improve total knee surgery. It is exciting to be part of a small med tech start up with a big vision to deliver accessible innovation to improve patient outcome for total knee patients across the globe.”
 
Tom Kitchen of Mercia adds: “With a more active, ageing population, demand for total knee replacements is growing rapidly but clearly success rates need to improve. Eventum’s device could offer a solution by removing the guesswork from surgery and providing accurate measurements. This is an exciting development and the fact that surgeons themselves are willing to invest in it is a major vote of confidence.”
 
The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank. 

Like this article? Sign up to our free newsletter Tags Deals & Transactions Healthcare & Life Sciences Investments

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.